ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
China’s HitGen has raised about $39 million in series B funding to grow its DNA-encoded libraries and advance its drug development programs. HitGen says it has more than 200 billion small molecules in over 900 libraries. The company has development programs in oncology, cardiovascular disease, respiratory disease, and metabolism. Its notable industry partners include BASF, Boehringer Ingelheim, Johnson & Johnson, Merck & Co., Pfizer, and Takeda.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter